Macro­Gen­ics chief Scott Koenig de­tails the up­beat can­cer drug da­ta from 2 pro­grams that drove a big spike in their share price

Macro­Gen­ics $MGNX dropped their AS­CO ab­stracts on 2 key drug pro­grams on Wednes­day evening, high­light­ing some ad­di­tion­al de­tails on da­ta that spurred their share price a cou­ple of days ago.

The sur­prise da­ta that cap­tured in­vestors’ at­ten­tion in­clude the news that 43% — 6 of 14 — of pa­tients with ad­vanced HER2 tu­mors demon­strat­ed an ob­jec­tive re­sponse to a com­bi­na­tion of mar­ge­tux­imab and MGD013 with 4 con­firmed re­spons­es and ev­i­dence of tu­mor shrink­age that could dri­ve that re­sponse rate even high­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.